N-[(3-{N'-[3,5-bis(trifluoromethyl)benzyl]-N'-(2-methyl-2H-tetrazol-5-yl)amino}methyl)quinolin-2-yl]-N-(cyclopentylmethyl)ethylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[(3-{N'-[3,5-bis(trifluoromethyl)benzyl]-N'-(2-methyl-2H-tetrazol-5-yl)amino}methyl)quinolin-2-yl]-N-(cyclopentylmethyl)ethylamine
• 英文别名: (3-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazole-5-yl)-amino]-methyl}-quinoline-2-yl)-cyclopentylmethyl-ethylamine；3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N-(cyclopentylmethyl)-N-ethylquinolin-2-amine
• 化学式: C₂₉H₃₁F₆N₇
• 分子量: 591.602
• InChiKey: OBHZXRGXOPEZJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  3,5-双三氟甲基苯甲醛 在 sodium tetrahydroborate 、 甲基磺酰氯 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 9.0h， 生成 N-[(3-{N'-[3,5-bis(trifluoromethyl)benzyl]-N'-(2-methyl-2H-tetrazol-5-yl)amino}methyl)quinolin-2-yl]-N-(cyclopentylmethyl)ethylamine
  参考文献：
  名称：

  WO2007/128568

  摘要：

  公开号：

文献信息

• Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
  申请人：OHGIYA Tadaaki

  公开号：US20090054474A1

  公开（公告）日：2009-02-26

  A compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: (wherein R 1 , R 2 , R 3 , R 4 and R 5 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R 6 , R 7 and R 8 are the same or different, and represent hydrogen atom, a halogen atom, a lower alkyl group etc., R 9 and R 10 are the same or different, and represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group etc., and R 11 represents hydrogen atom, a halogen atom, a lower alkoxy group, a (lower alkyl)thio(lower alkoxy) group, a (lower alkyl)sulfinyl(lower alkoxy) group, a (lower alkyl)sulfonyl(lower alkoxy) group etc.), which has potent inhibitory activity on CETP.

  由以下一般式（I）表示的化合物或其盐，或其溶剂合物：（其中R1、R2、R3、R4和R5相同或不同，代表氢原子、卤原子、较低烷基等，R6、R7和R8相同或不同，代表氢原子、卤原子、较低烷基等，R9和R10相同或不同，代表氢原子、较低烷基、（较低环烷基）（较低烷基）等，R11代表氢原子、卤原子、较低烷氧基、（较低烷基）硫（较低烷氧基）基、（较低烷基）亚硫基（较低烷氧基）基、（较低烷基）砜基（较低烷氧基）基等），对CETP具有强大的抑制活性。
• Novel benzylamine derivatives as CETP inhibitors
  申请人：Baruah Anima

  公开号：US20060178514A1

  公开（公告）日：2006-08-10

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了包括新的苄胺化合物、含有苄胺化合物的组合物、制备苄胺化合物的方法以及使用苄胺化合物治疗或预防与脂蛋白代谢相关的多种疾病或症状的方法等。
• Bicyclic derivatives as CETP inhibitors
  申请人：Kishida Masashi

  公开号：US20090227580A1

  公开（公告）日：2009-09-10

  The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.

  本发明涉及式(I)的新化合物或其药物组合物，其中所有变量在文本中定义。本发明进一步涉及使用本发明中的化合物治疗或延缓与CETP有关的疾病的进展。
• Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
  申请人：Baruah Anima

  公开号：US20070015758A1

  公开（公告）日：2007-01-18

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• BICYCLIC DERIVATIVES AS CETP INHIBITORS
  申请人：KISHIDA Masashi

  公开号：US20120225874A1

  公开（公告）日：2012-09-06

  The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.

  本发明涉及公式（I）的新化合物或其药物组成物，其中所有变量在文本中定义。本发明还涉及将本化合物用于治疗或延缓CETP参与的疾病的进展。